- Home
- RERE vs HELP Comparison
RERE vs HELP Comparison
Compare RERE & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | HELP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 889.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RERE | HELP |
|---|---|---|
| Price | $3.94 | $13.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 748.0K | ★ 1.7M |
| Earning Date | 05-19-2026 | 07-01-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $3.76 |
| 52 Week High | $6.47 | $15.15 |
Technical Indicators
Market Signals| Indicator | RERE | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 59.90 |
| Support Level | $3.86 | $4.41 |
| Resistance Level | $4.33 | $14.35 |
| Average True Range (ATR) | 0.10 | 1.08 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 12.66 | 69.15 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.